Literature DB >> 10794728

Designing transthyretin mutants affecting tetrameric structure: implications in amyloidogenicity.

C Redondo1, A M Damas, M J Saraiva.   

Abstract

The molecular mechanisms that convert soluble transthyretin (TTR) tetramers into insoluble amyloid fibrils are still unknown; dissociation of the TTR tetramer is a pre-requisite for amyloid formation in vitro and involvement of monomers and/or dimers in fibril formation has been suggested by structural studies. We have designed four mutated proteins with the purpose of stabilizing [Ser(117)-->Cys (S117C) and Glu(92)-->Cys (E92C)] or destabilizing [Asp(18)-->Asn (D18N) and Leu(110)-->Ala (D110A)] the dimer/tetramer interactions in TTR, aiming at elucidating structural determinants in amyloidogenesis. The resistance of the mutated proteins to dissociation was analysed by HPLC studies of diluted TTR preparations. Both 'stabilized' mutants migrated as tetramers and, upon dilution, no other TTR species was observed, confirming the increased resistance to dissociation. For the 'destabilized' mutants, a mixture of tetrameric and monomeric forms co-existed at low dilution and the latter increased upon 10-fold dilution. Both of the destabilizing mutants formed amyloid in vitro when acidified. This result indicated that both the AB loop of TTR, destabilized in D18N, and the hydrophobic interactions affecting the dimer-dimer interfaces in L110A are implicated in the stability of the tetrameric structure. The stabilized mutants, which were dimeric in nature through disulphide bonding, were unable to polymerize into amyloid, even at pH 3.2. When the amyloid formation assay was repeated in the presence of 2-mercaptoethanol, upon disruption of the S-S bridges of these stable dimers, amyloid fibril formation was observed. This experimental evidence suggests that monomers, rather than dimers, are the repeating structural subunit comprising the amyloid fibrils.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10794728      PMCID: PMC1221050     

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  18 in total

Review 1.  Molecular genetics of familial amyloidotic polyneuropathy.

Authors:  M J Saraiva
Journal:  J Peripher Nerv Syst       Date:  1996       Impact factor: 3.494

2.  Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein.

Authors:  H L Monaco; M Rizzi; A Coda
Journal:  Science       Date:  1995-05-19       Impact factor: 47.728

3.  Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A.

Authors:  C C Blake; M J Geisow; S J Oatley; B Rérat; C Rérat
Journal:  J Mol Biol       Date:  1978-05-25       Impact factor: 5.469

4.  Production of recombinant human transthyretin with biological activities toward the understanding of the molecular basis of familial amyloidotic polyneuropathy (FAP).

Authors:  H Furuya; M J Saraiva; M A Gawinowicz; I L Alves; P P Costa; H Sasaki; I Goto; Y Sakaki
Journal:  Biochemistry       Date:  1991-03-05       Impact factor: 3.162

5.  Structure of the Val122Ile variant transthyretin - a cardiomyopathic mutant.

Authors:  A M Damas; S Ribeiro; V S Lamzin; J A Palha; M J Saraiva
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1996-09-01

6.  Thyroxine binding to transthyretin Met 119. Comparative studies of different heterozygotic carriers and structural analysis.

Authors:  M R Almeida; A M Damas; M C Lans; A Brouwer; M J Saraiva
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

7.  Analysis of x-ray diffraction patterns from amyloid of biopsied vitreous humor and kidney of transthyretin (TTR) Met30 familial amyloidotic polyneuropathy (FAP) patients: axially arrayed TTR monomers constitute the protofilament.

Authors:  H Inouye; F S Domingues; A M Damas; M J Saraiva; E Lundgren; O Sandgren; D A Kirschner
Journal:  Amyloid       Date:  1998-09       Impact factor: 7.141

8.  The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.

Authors:  Z Lai; W Colón; J W Kelly
Journal:  Biochemistry       Date:  1996-05-21       Impact factor: 3.162

9.  'In vitro' amyloid fibril formation from transthyretin: the influence of ions and the amyloidogenicity of TTR variants.

Authors:  M J Bonifácio; Y Sakaki; M J Saraiva
Journal:  Biochim Biophys Acta       Date:  1996-05-24

10.  Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 A resolution.

Authors:  A Wojtczak; V Cody; J R Luft; W Pangborn
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1996-07-01
View more
  5 in total

Review 1.  Disorder-to-order conformational transitions in protein structure and its relationship to disease.

Authors:  Paola Mendoza-Espinosa; Victor García-González; Abel Moreno; Rolando Castillo; Jaime Mas-Oliva
Journal:  Mol Cell Biochem       Date:  2009-04-09       Impact factor: 3.396

2.  Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor.

Authors:  Luís Gales; Sandra Macedo-Ribeiro; Gemma Arsequell; Gregorio Valencia; Maria João Saraiva; Ana Margarida Damas
Journal:  Biochem J       Date:  2005-06-01       Impact factor: 3.857

3.  Considerably Unfolded Transthyretin Monomers Preceed and Exchange with Dynamically Structured Amyloid Protofibrils.

Authors:  Minna Groenning; Raul I Campos; Daniel Hirschberg; Per Hammarström; Bente Vestergaard
Journal:  Sci Rep       Date:  2015-06-25       Impact factor: 4.379

4.  Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin.

Authors:  Jeffrey N Higaki; Avi Chakrabartty; Natalie J Galant; Kevin C Hadley; Bradley Hammerson; Tarlochan Nijjar; Ronald Torres; Jose R Tapia; Joshua Salmans; Robin Barbour; Stephen J Tam; Ken Flanagan; Wagner Zago; Gene G Kinney
Journal:  Amyloid       Date:  2016-03-16       Impact factor: 7.141

5.  Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.

Authors:  Ricardo Sant'Anna; Maria Rosário Almeida; Nathalia Varejāo; Pablo Gallego; Sebastian Esperante; Priscila Ferreira; Alda Pereira-Henriques; Fernando L Palhano; Mamede de Carvalho; Debora Foguel; David Reverter; Maria João Saraiva; Salvador Ventura
Journal:  Sci Rep       Date:  2017-03-24       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.